Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Retinal Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDC Mutant / WT Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PDC Products |
| Gene Delivery | PDC Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PDC Products |
| Benchmark Ab | Anti-PDC Recombinant positive control. |
View PDC Products |
| Validator | PDC siRNA Set For knockdown verification. |
View PDC Products |
| Related Target A | GNAT1 G-protein alpha subunit interacting in phototransduction |
View GNAT1 Products |
| Related Target B | RHO Rhodopsin pathway synergy |
View RHO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| G-protein Binding Assays | High-purity (>95%) recombinant PDC for precise SPR/BLI affinity measurements |
| Intracellular Target Validation | Sequence Verified full-length ORF Lentivirus for cellular assays |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization |
| False Positives | Validated siRNA included for specificity checks |
Live PDC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDC (Phosducin) therapeutics is intensifying, with major players shifting focus from traditional small molecules to Gene Therapy and ASO modalities. As first-generation therapies reach the clinic for retinal dystrophies, the next wave of R&D is targeting precise modulation of G-protein coupled cascades in the retina.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy | Ocular Gene Therapy Biotechs | Retinal Degeneration | Expression Validation (Need specific Abs & Lentivirus) |
| Small Molecule | Specialty Pharma | Vision Loss | Binding Assay (Need High-Purity Proteins) |
| ASO / siRNA | RNAi Leaders | Inherited Retinal Diseases | Knockdown Validation (Need validated siRNA) |